×
About 33,101 results

ALLMedicine™ Hodgkin Lymphoma Center

Research & Reviews  15,307 results

Microbial dysbiosis is associated with aggressive histology and adverse clinical outcom...
https://doi.org/10.1182/bloodadvances.2020003129
Blood Advances; Diefenbach CS, Peters BA et. al.

Feb 26th, 2021 - B-cell non-Hodgkin lymphoma cell survival depends on poorly understood immune evasion mechanisms. In melanoma, the composition of the gut microbiota (GMB) is associated with immune system regulation and response to immunotherapy. We investigated t...

Classic Hodgkin lymphoma in Guatemalan children of age less than six years: analysis of...
https://doi.org/10.1080/10428194.2021.1885666
Leukemia & Lymphoma; Silva O, Charu V et. al.

Feb 25th, 2021 - Classic Hodgkin lymphoma (cHL) in young children (ages 0-6) is rare in high income countries (HICs) but is more prevalent in low- and middle-income countries (LMICs) like Guatemala. Given that the majority of cHL studies have evaluated adolescent/...

Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morb...
https://doi.org/10.1200/JCO.20.01186
Journal of Clinical Oncology : Official Journal of the Am... Oeffinger KC, Stratton KL et. al.

Feb 25th, 2021 - To determine the incidence of serious chronic health conditions among survivors of pediatric Hodgkin lymphoma (HL), compare by era of therapy and by selected cancer therapies, and provide estimates of risks associated with contemporary therapy. As...

Markers of Follicular Helper T Cells Are Occasionally Expressed in T-Cell or Histiocyte...
https://doi.org/10.1093/ajcp/aqaa249
American Journal of Clinical Pathology; Abukhiran I, Syrbu SI et. al.

Feb 24th, 2021 - Follicular helper T cell (TFH) markers are expressed in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma of the TFH phenotype (PTCL-TFH). However, differential expression and coexpression of these markers in benign and othe...

see more →

Guidelines  111 results

Adult Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq?cid=eb_govdel
National Cancer Institute

Jan 14th, 2021 - More than 75% of all newly diagnosed patients with adult HL can be cured with combination chemotherapy and/or radiation therapy.[2] Over the last five decades, U.S. national mortality has fallen more rapidly for adult HL than for any other maligna...

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma
https://www.mdedge.com/hematology-oncology/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab

May 31st, 2020 - Pembrolizumab treatment significantly improved progression-free survival versus brentuximab vedotin in a recent randomized, phase 3 trial including patients with relapsed or refractory classical Hodgkin lymphoma, an investigator has reported.

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 30th, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 30th, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

see more →

Drugs  79 results see all →

Clinicaltrials.gov  16,507 results

Microbial dysbiosis is associated with aggressive histology and adverse clinical outcom...
https://doi.org/10.1182/bloodadvances.2020003129
Blood Advances; Diefenbach CS, Peters BA et. al.

Feb 26th, 2021 - B-cell non-Hodgkin lymphoma cell survival depends on poorly understood immune evasion mechanisms. In melanoma, the composition of the gut microbiota (GMB) is associated with immune system regulation and response to immunotherapy. We investigated t...

Classic Hodgkin lymphoma in Guatemalan children of age less than six years: analysis of...
https://doi.org/10.1080/10428194.2021.1885666
Leukemia & Lymphoma; Silva O, Charu V et. al.

Feb 25th, 2021 - Classic Hodgkin lymphoma (cHL) in young children (ages 0-6) is rare in high income countries (HICs) but is more prevalent in low- and middle-income countries (LMICs) like Guatemala. Given that the majority of cHL studies have evaluated adolescent/...

Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morb...
https://doi.org/10.1200/JCO.20.01186
Journal of Clinical Oncology : Official Journal of the Am... Oeffinger KC, Stratton KL et. al.

Feb 25th, 2021 - To determine the incidence of serious chronic health conditions among survivors of pediatric Hodgkin lymphoma (HL), compare by era of therapy and by selected cancer therapies, and provide estimates of risks associated with contemporary therapy. As...

Markers of Follicular Helper T Cells Are Occasionally Expressed in T-Cell or Histiocyte...
https://doi.org/10.1093/ajcp/aqaa249
American Journal of Clinical Pathology; Abukhiran I, Syrbu SI et. al.

Feb 24th, 2021 - Follicular helper T cell (TFH) markers are expressed in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma of the TFH phenotype (PTCL-TFH). However, differential expression and coexpression of these markers in benign and othe...

see more →

News  1,093 results

Remission of Hodgkin Lymphoma After COVID-19
https://www.medscape.com/viewarticle/945856

Feb 15th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Patients with cancer are considered at risk for COVID-19, but in some cases, could the infection be a good thing? A case report of a patient with ...

Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes
https://www.medscape.com/viewarticle/945496

Feb 8th, 2021 - NEW YORK (Reuters Health) - Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection, according to a study from France. "More than 20 years ...

Fast Five Quiz: Waldenström Macroglobulinemia Workup
https://reference.medscape.com/viewarticle/944100

Jan 31st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...

Adult Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq?cid=eb_govdel
National Cancer Institute

Jan 14th, 2021 - More than 75% of all newly diagnosed patients with adult HL can be cured with combination chemotherapy and/or radiation therapy.[2] Over the last five decades, U.S. national mortality has fallen more rapidly for adult HL than for any other maligna...

Model May Predict Post-treatment Hodgkin Lymphoma Outcomes
https://www.medscape.com/viewarticle/942505

Dec 10th, 2020 - Combining positron emission tomography (PET) with tumour gene expression profiling straight after treatment may be able to identify which patients with early stage classical Hodgkin lymphoma (cHL) are likely to experience disease progression or an...

see more →

Patient Education  4 results see all →